Impact Factor 3.845 | CiteScore 3.92
More on impact ›
Frontiers in “Gastrointestinal and Hepatic Pharmacology” welcomes articles concerned with the experimental and clinical pharmacology in the fields of the alimentary tract, the liver, biliary tree and pancreas.Read More
Frontiers in “Gastrointestinal and Hepatic Pharmacology” welcomes articles concerned with the experimental and clinical pharmacology in the fields of the alimentary tract, the liver, biliary tree and pancreas. The manuscripts should have a direct bearing on the effect, mode of action or therapeutic use of drugs as well as on the identification of novel pharmacological targets. The definition of “drugs” will include existing drugs, compounds under development, naturally-occurring molecules, nutraceuticals, probiotics and standardized plant extracts (with the identification of the active ingredient(s) responsible for the pharmacological activity).
Topics range from – but are not limited to – cell growth and regeneration, immune system, motor function, fibrogenesis, carcinogenesis and secretion. Mechanisms which contribute to gastrointestinal sensations (such as taste, appetite, nausea and pain), acid secretion and gastrointestinal motility are also included. Review articles on potential targets and drug classes will be encouraged. All aspects of translation will be relevant, including comparisons between recombinant and native receptor functions, between animal and human biology, and between in vitro predictions and in vivo efficacy.
The mission is to be inclusive, and bring all relevant sub-specialties in pharmacology onto a single gastrointestinal-liver platform.
Indexed in: PubMed, PubMed Central, Scopus, Web of Science, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS)
PMCID: all published articles receive a PMCID
Gastrointestinal and Hepatic Pharmacology welcomes submissions of the following article types: Brief Research Report, Clinical Trial, Correction, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Study Protocol and Technology and Code.
All manuscripts must be submitted directly to the section Gastrointestinal and Hepatic Pharmacology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Gastrointestinal and Hepatic Pharmacology will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Pharmacology.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com